Source: Annual Congress 2008 - Pulmonary vascular medicine
Disease area: Airway diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Ulrich, M. Fischler, M. Hersberger, U. Treder, E. W. Russi, R. Speich (Zurich, Switzerland). Polymorphism of the serotonin transporter and 2a receptor gene in COPD with and without pulmonary hypertension. Eur Respir J 2008; 32: Suppl. 52, 1584

Member's Comments

No comment yet.

Related content which might interest you: Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive lung disease Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003 Estrogen receptor alpha gene polymorphisms and primary pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 352s Year: 2005 Overexpression of serotonin receptor 1B (5HT-1B) responsible for overflow induced experimental pulmonary arterial hypertension development Source: Annual Congress 2003 - Pathophysiology of the pulmonary circulation Year: 2003 Mice over-expressing the 5-HT transporter gene develop pulmonary hypertension Source: Annual Congress 2004 - Pathophysiology of pulmonary hypertension Year: 2004 Effect of dexfenfluramine on the development of pulmonary hypertension in mice over-expressing the serotonin transporter Source: Eur Respir J 2005; 26: Suppl. 49, 352s Year: 2005 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Single centre experience with endothelin receptor blockade in pulmonary hypertension Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Microarray analysis of pulmonary gene expression in mice lacking the vasoactive intestinal peptide (VIP) gene: confirmation of a role in asthma and pulmonary arterial hypertension (PAH) Source: Annual Congress 2006 - Cellular mechanisms of airway disease Year: 2006 Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation Source: Eur Respir J 2003; 22: 560-562 Year: 2003 Dual endothelin receptor antagonism: setting standards in PAH Source: Eur Respir Rev 2008; 17: 13-18 Year: 2007 Expression of the serotonin 1b receptor in experimental pulmonary hypertension Source: Eur Respir J 2003; 22: 408-412 Year: 2003 Interleukin-1b and interleukin-1 receptor antagonist gene polymorphisms in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 136s Year: 2004 Endothelin-a receptor antagonists reduce eNOS gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 271s Year: 2003 Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension? Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018 Year: 2018 Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Endothelin receptor antagonists in pulmonary arterial hypertension Source: Eur Respir J 2008; 31: 407-415 Year: 2008 Relationship between Galectin-3 and mineralocorticoid receptor in pulmonary hypertension Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020